| Patient | Pierre Le Moyne d'Iberville |
|---|---|
| Date of birth | 1982-07-16 |
| Identifiers | MRN HR-ET014-SYN; SSN (made up) 000-14-7260 |
| Document date | 2026-03-03 |
| Author | Marguerite Delacroix-Boateng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week follow-up of recurrent fevers, seen the same day in infectious diseases. [S]
Mr. Le Moyne d'Iberville returns two weeks after his first visit, on the day of his infectious diseases consultation with Dr. Okonkwo-Hale. He has had no fever, chills or sweats since then. The intake blood smears and rapid antigen test were negative, and the PCR sent to the reference laboratory at intake has detected Plasmodium vivax DNA. His quantitative G6PD activity is normal. He is not on any medicine and has no allergies. He is keen to be treated before the squadron's preparations take up all his time. [S]
| Element | Detail |
|---|---|
| Fever | None since intake |
| Results | Smears and rapid antigen test negative; PCR detected P. vivax DNA; G6PD normal |
| Medicines | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, chills or sweats; tired at the end of the day |
| Gastrointestinal | Negative | No abdominal pain or jaundice |
| Genitourinary | Negative | No dark urine |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 2026-03-03 to 2026-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 2026-03-03 to 2026-03-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 175 | cm | S |
| 2026-03-03 | Body weight | 68.6 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 68 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.6 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-03-03; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/76, pulse 68, weight 68.6 kg |
| Eyes | Sclerae white; mild conjunctival pallor |
| Abdomen | Spleen tip not palpable; liver not enlarged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed | R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | active | confirmed | B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed | Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Malaria diagnosis: smears, rapid antigen test and species PCR | At diagnosis | Completed today | Smears and rapid antigen test negative at intake; PCR from the intake sample detected P. vivax DNA |
| Laboratory | Quantitative G6PD activity before primaquine or tafenoquine | Once, before an 8-aminoquinoline | Completed today | 11.8 U/g Hb at intake, normal |
| Laboratory | Blood count and bilirubin for hemolysis on primaquine | Baseline, then after the course | Up to date | Hemoglobin 13.0 g/dL, platelets 141 x10^3/uL and bilirubin 1.1 mg/dL at intake; repeat after primaquine |
| Referral | Infectious diseases (travel medicine) consultation | Once | Completed today | Seen by Dr. Okonkwo-Hale today |
| Medication safety | Adverse effects: nausea, abdominal pain, dark urine, breathlessness, cyanosis | During the course | Completed today | Counseled before the first doses; take with food |
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | Fever card given: a smear the same day for any fever |
| Laboratory | Follow-up blood smear after treatment (ideally within one week of finishing) | About one week after finishing | Ordered | Smear and PCR ordered for a week after the last primaquine dose |
Goal progress:
Guideline basis: Treatment of Uncomplicated Malaria (clinical guidance) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006)
Follow-up: Review in four weeks. Next scheduled visit 2026-03-31: six-week review after chloroquine and primaquine: blood count, adverse effects, relapse surveillance. [S]